MedPath

Identification of Prognostic Gene Mutations in Biliary Tract Cancer Using Whole Genome Sequencing

Conditions
Biliary Tract Cancer
Registration Number
NCT03718897
Lead Sponsor
Ji Kon Ryu
Brief Summary

The purpose of this study is to investigate genetic mutations affecting prognosis using whole genome sequencing in patients with biliary tract cancer.

Detailed Description

Recently, as genome technology such as next-generation sequencing has progressed, precision medicine using genetic analysis in lung cancer, colorectal cancer, and melanoma has been actively studied. The need for such precision medicine is also increasing in biliary tract cancer patients. Although whole genome sequencing is relatively costly, it is known to provide more accurate information than other methods such as exome analysis and RNA sequencing in identifying promoter mutations, regulatory regions, and structural variants. Pancreatic cancer and melanoma have been studied by whole genome sequencing, but there is no previous study using whole genome sequencing method in biliary tract cancer.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Patients diagnosed with biliary tract cancer via endoscopic retrograde cholangiopancreatogram
Exclusion Criteria
  • Pregnancy
  • Other active tumors within 5 years
  • Coagulopathy
  • Severe mental illness

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Overall survival rate48 months

Comparisons of overall survival rates between patients with gene mutations and without.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath